Glaucoma-Intraocular Pressure Reduction

Huang, Alex S.; Minasyan, Lilit; Weinreb, Robert N.

doi:10.1007/164_2016_24

Cited by 10 publications

(3 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The control group included all participants who did not have any claims records of anti‐glaucoma medications from 2004 to 2016. Considering that medical treatments are widely used for the management of glaucoma, 22 those without any anti‐glaucoma medications prescribed during the 12 years were unlikely to be glaucoma patients with glaucoma. In order to control major confounding factors and improve statistical efficiency, every participant with glaucoma onset was matched with two randomly selected controls by age (± 1 year), gender and self‐reported cardiovascular diseases (CVD) at baseline.…”

Section: Methodsmentioning

confidence: 99%

Use of antihypertensive medications and the risk of glaucoma onset: Findings from the 45 and Up Study

Yuan

Wang

Shang

et al. 2022

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Background Abnormal blood pressure is a potential risk factor for glaucoma. However, the role of antihypertensive medications on glaucoma pathogenesis is controversial. This study aims to investigate the association between the use of antihypertensive medications and glaucoma onset. Methods This nested case–control study, based on a large‐scale longitudinal cohort in Australia, retrieved participants' claims records on drugs and Medicare services from national health databases. Participants with three or more claim records of anti‐glaucoma medications from 2009 to 2016 were classified as glaucoma patients; those with none were classified as controls. Claim records of antihypertensive medications were identified within the 5 years before glaucoma onset and contemporary periods in matched controls without glaucoma. The association between the use of antihypertensive medications and glaucoma onset was assessed by multivariable logistic regression models. Results A total of 6748 cases and 13 496 controls were analysed. Compared with controls, the proportion of users of antihypertensive medications was slightly higher in glaucoma patients (46.9% vs. 46.0%, p > 0.05). After adjustments for demographics, health‐related factors and medical history, the association between the use of antihypertensive medications and glaucoma onset was nonsignificant (OR 0.95, 95% CI = 0.89–1.02). As for specific subtypes, only beta‐blocking agents (BBA) (OR 0.82, 95% CI = 0.75–0.90) and diuretics (OR 0.85, 95% CI = 0.77–0.95) were significantly associated with reduced risks of glaucoma onset. Conclusions This study indicated that the use of antihypertensive medications was not associated with glaucoma onset. Decreased risks of glaucoma onset in users of BBA and diuretics require further validation.

show abstract

Section: Methodsmentioning

confidence: 99%

Use of antihypertensive medications and the risk of glaucoma onset: Findings from the 45 and Up Study

Yuan

Wang

Shang

et al. 2022

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

“…In glaucomatous optic neuropathy, one of the leading causes of blindness worldwide, IOP causes eye tissue stress, deformations and strain, leading eventually to damage and loss of retinal ganglion cell axons ( Sigal and Ethier, 2009 ; Figure 1 ). IOP reduction remains the only therapy used to preserve vision and retard glaucomatous progression ( Huang et al, 2017 ). This suggests that the biomechanical effects of IOP to the tissues surrounding the optic nerve head are central to disease ( Sigal, 2009 ).…”

Section: Mechanotransduction In Central Nervous System Pathologymentioning

confidence: 99%

Mechanotransduction: Exploring New Therapeutic Avenues in Central Nervous System Pathology

et al. 2022

View full text Add to dashboard Cite

Cells are continuously exposed to physical forces and the central nervous system (CNS) is no exception. Cells dynamically adapt their behavior and remodel the surrounding environment in response to forces. The importance of mechanotransduction in the CNS is illustrated by exploring its role in CNS pathology development and progression. The crosstalk between the biochemical and biophysical components of the extracellular matrix (ECM) are here described, considering the recent explosion of literature demonstrating the powerful influence of biophysical stimuli like density, rigidity and geometry of the ECM on cell behavior. This review aims at integrating mechanical properties into our understanding of the molecular basis of CNS disease. The mechanisms that mediate mechanotransduction events, like integrin, Rho/ROCK and matrix metalloproteinases signaling pathways are revised. Analysis of CNS pathologies in this context has revealed that a wide range of neurological diseases share as hallmarks alterations of the tissue mechanical properties. Therefore, it is our belief that the understanding of CNS mechanotransduction pathways may lead to the development of improved medical devices and diagnostic methods as well as new therapeutic targets and strategies for CNS repair.

show abstract

“…[1][2][3] Primary openangle glaucoma (POAG), the most common subset of glaucoma, develops due to chronically elevated IOP, which is caused by an abnormally high resistance to aqueous humor (AH) drainage through trabecular meshwork (TM) outflow pathways. [4][5][6] This resistance appears to be associated with the juxtacanalicular portion of the TM-mediated extracellular matrix and endothelial-lined Schlemm's canal, which is responsible for the conventional outflow. 7,8 Pharmacologic lowering of IOP has been demonstrated to reduce the risk of POAG progression.…”

mentioning

confidence: 99%

A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia

Hsu

Chen²,

Liu³

et al. 2019

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

The purpose of this study was to investigate the IOP-lowering effects of the ITRI-E-212, a new Rho-associated protein kinase (ROCK) inhibitor. ITRI-E-212 improved fluid outflow through the trabecular meshwork and reduced IOP with transient and mild conjunctival hyperemia. ITRI-E-212 can potentially be developed into new antiglaucoma agents. METHODS. ITRI-E-212 was selected from more than 200 amino-isoquinoline structures because of its adequate solubility and drug-loading percentage in eye drops. ITRI-E-212 has less than 50% inhibitory concentration (IC 50) against ROCK2. The in vitro kinase inhibition was evaluated using the ADP-Glo kinase assay. A comprehensive analysis of the kinase inhibitor selectivity of ITRI-E-212 was performed using the KINOMEscan methodology. The IOPlowering effect and tolerability of ITRI-E-212 were investigated in normotensive and ocular hypertensive rabbits. The pharmacokinetics study was performed in vivo in the aqueous humor (AH), and hyperemia was assessed. RESULTS. ITRI-E-212 showed high in vitro inhibitory activity against ROCK2 and high specificity against AGC kinases. The mean IOP-lowering effect of ITRI-E-212 in normotensive and ocular hypertensive models was 24.9% and 28.6%, respectively; 1% ITRI-E-212 produced notable reductions in IOP that were sustained for at least 6 hours after each dose once per day. Only transient, mild hyperemia was observed. The compound extracted from the AH reached 78.4% ROCK2 kinase inhibition at 1 hour after dose administration and was sustained for 4 hours. CONCLUSIONS. ITRI-E-212 is a novel and highly specific ROCK2 inhibitor with the ability to lower IOP in animal models. It has favorable pharmacokinetic and ocular tolerability profiles with only minimal conjunctival hyperemia.

show abstract

Glaucoma-Intraocular Pressure Reduction

Cited by 10 publications

References 116 publications

Use of antihypertensive medications and the risk of glaucoma onset: Findings from the 45 and Up Study

Use of antihypertensive medications and the risk of glaucoma onset: Findings from the 45 and Up Study

Mechanotransduction: Exploring New Therapeutic Avenues in Central Nervous System Pathology

A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia

Contact Info

Product

Resources

About